Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in January and February 2017.
Abbisko brings in $28mm via Series A
China-based Abbisko Therapeutics raised $28mm through its Series A financing to Lilly Asia Ventures, Sinopharm Capital, Jianxin Capital, and...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.
CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.
Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.
The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.
The osteogenesis imperfecta drug stumbled in a second interim analysis.
Recent moves in the industry include C-suite changes at Essential Pharma, plus Kyverna Therapeutics gets new chief financial officer from Alector.
The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.
